Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset-Reference-Cited by-同舟云学术

Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset

Published:2014 Issue:1 Volume:16 Page:R23
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Dominguez-Gutierrez Paul R,Ceribelli Angela,Satoh Minoru,Sobel Eric S,Reeves Westley H,Chan Edward KL

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference49 articles.

1. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

2. Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood

3. Interferon pathway activation in systemic lupus erythematosus

4. Systemic Lupus Erythematosus: Presence in Human Serum of an Unusual Acid-Labile Leukocyte Interferon

5. Activation of the interferon-γ signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical significance of serum CXCL9, CXCL10, and CXCL11 in patients with lupus nephritis;Immunity, Inflammation and Disease;2024-08

2. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider;RMD Open;2023-03

3. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider;RMD Open;2023-03

4. The role of non-coding RNA in lupus nephritis;Human Cell;2023-02-25

5. Monocyte subsets and monocyte-related chemokines in Takayasu arteritis;Scientific Reports;2023-02-06